BOSTON--(BUSINESS WIRE)--VoxNeuro Inc. (“VoxNeuro” or the “Company”), a commercial stage Software-as-a-Medical-Device (SaMD) brain health company that analyzes brain biomarkers to assess cognitive function, announced a new partnership with Boston University (“BU”), a world-class institution and private research university at the forefront of neuroscience and neurotechnology.
In partnership with BU, VoxNeuro has launched two studies that will evaluate its cognitive health assessment platform in an outpatient setting to assess diagnostic accuracy. The studies will focus on patients suffering from mild-Traumatic Brain Injury (mTBI)/Concussion and Alzheimer’s disease, respectively.
On a combined basis, mTBI/Concussion and Alzheimer’s disease affect over ten million Americans annually, and the inefficiencies of current behavior-based screening methodologies results in considerable excess cost and time to patients, clinicians and the healthcare system. VoxNeuro’s cognitive health software is expected to provide additive diagnostic information to improve clinical management beyond traditional testing methods. This represents a significant step forward for brain health as VoxNeuro provides for better identification and management strategies.
The studies will be led by Dr. John Connolly, PhD, VoxNeuro’s Chief Science Officer and Dr. Kyle Ruiter, PhD, VoxNeuro’s Vice President of Clinical & Scientific Affairs, alongside co-investigators Dr. Andrew Budson, MD, Professor of Neurology at Boston University School of Medicine and Associate Director of Boston University’s Alzheimer’s Disease Research Center, and Dr. Katherine Turk, MD, Assistant Professor of Neurology at Boston University School of Medicine and co-Leader of the Outreach, Recruitment and Engagement Core at the Boston University Alzheimer’s Disease Research Center.
“We are excited to test the hypothesis that by combining EEG brainwaves and cognitive testing clinicians may be able to diagnose correctly who is suffering from Alzheimer’s disease or a brain injury in a manner that may not require a research laboratory to interpret the data,” said Dr. Budson.
Dr. Ruiter echoed this excitement, saying, “we are thrilled to be partnering with Boston University, an institution that continues to be at the head of neuroscience research, discovery and innovation. BU’s best-in-class team is a pillar of Boston’s globally recognized biotech hub and through our collaboration with them we anticipate rich insights into VoxNeuro’s unique and proprietary data sets that will help drive the development of our second-generation product. Together, we are going to continue to push the boundaries of brain health through innovation.”
VoxNeuro anticipates that this will continue to enhance its market awareness and will improve the ability of clinicians to accurately diagnose, treat, and aid in the management of patients suffering from mTBI/Concussion and Alzheimer’s disease. The Company also anticipates that this work may support new regulatory filings with the FDA and Health Canada.
About VoxNeuro – Give the Brain a Voice
VoxNeuro is pushing the boundaries of brain health and empowering healthcare providers with a breakthrough SaMD technology that uses validated brain biomarkers. The Company’s EEG-based reports deliver a comprehensive understanding of how a brain is functioning through the objective measurement of a patient’s attention and concentration, information processing, and working memory. VoxNeuro complements existing clinical workflow to provide clinicians and patients with a more complete picture of brain health, and to inform clinical decision-making.
Visit voxneuro.com to learn more.
Forward-Looking Statements
Certain statements contained in this press release may constitute forward-looking statements under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. These forward-looking statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. Accordingly, the actual events may differ materially from those projected in the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward-looking statements, except as may be required by applicable securities laws.
